Taurohyocholic Acid (Synonyms: Tauro-γ-muricholic Acid) |
|
Katalog-Nr.GC45574
|
Taurohyocholic Acid ist eine Taurinkonjugierte Gallensäure, die vorwiegend in der Galle von Schweinen gefunden wird und aus Hyocholic Säure hergestellt wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 32747-07-2
Sample solution is provided at 25 µL, 10mM.
Taurohyocholic Acid ist eine Taurinkonjugierte Gallensäure, die vorwiegend in der Galle von Schweinen gefunden wird und aus Hyocholic Säure hergestellt wird.[1] . Taurohyocholsäure spielt eine entscheidende Rolle bei der Glukose-Hom öostase[2] und der metabolischen Regulation [3]. Sie wird auch in der Forschung der OnkologieIt[4] und der Nierenerkrankung im Endstadium (ESRD)[5] als Biomarker zur Vorhersage der Wirksamkeit der Behandlung verwendrt.
Taurohyocholic Acid stimuliert die Produktion und Sekretion von GLP-1 in intestinalen enteroendokrinen STC-1- und NCI-H716-Zellen, indem sie die Proglucagon-Transkription fördert. In STC-1- und NCI-H716-Zellen erhöhte die Behandlung mit 25M Taurohyocholsäure für 1 Stunde signifikant GLP-1 Sekretion und eine 24-stündige Inkubation förderten die Proglucagon-Transkription und die GLP-1-Produktion weiter[6].
References:
[1]. Fang W, Wen X, Meng Q, et al. Alteration in bile acids profile in Large White pigs during chronic heat exposure. J Therm Biol. 2019 Aug;84:375-383. doi: 10.1016/j.jtherbio.2019.07.027. Epub 2019 Jul 26. PMID: 31466777.
[2]. Cheng Z, Liu G, Zhang X, et al. Improvement of Glucose Metabolism Following Long-Term Taurocholic Acid Gavage in a Diabetic Rat Model. Med Sci Monit. 2018 Oct 9;24:7206-7212. doi: 10.12659/MSM.912429. PMID: 30298865; PMCID: PMC6192455.
[3]. Zheng X, Chen T, Zhao A, et al. Hyocholic acid species as novel biomarkers for metabolic disorders. Nat Commun. 2021 Mar 5;12(1):1487. doi: 10.1038/s41467-021-21744-w. PMID: 33674561; PMCID: PMC7935989.
[4]. Chen Y, Wang Y, Lei J, et al. Taurohyocholic acid acts as a potential predictor of the efficacy of tyrosine kinase inhibitors combined with programmed cell death-1 inhibitors in hepatocellular carcinoma. Front Pharmacol. 2024 Feb 23;15:1364924. doi: 10.3389/fphar.2024.1364924. PMID: 38464731; PMCID: PMC10920247.
[5]. Chen WY, Zhang JH, Chen LL, et al. Bioactive metabolites: a clue to the link between MASLD and CKD? Clin Mol Hepatol. 2024 Oct 21. doi: 10.3350/cmh.2024.0782. Epub ahead of print. PMID: 39428978.
[6]. Zheng X, Chen T, Jiang R, et al. Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism. Cell Metab. 2021 Apr 6;33(4):791-803.e7. doi: 10.1016/j.cmet.2020.11.017. Epub 2020 Dec 17. PMID: 33338411.
| Zellexperiment [1]: | |
Zelllinien | STC-1 |
Vorbereitungsmethode | Die STC-1 Zellen wurden in 24-Steckige Mikronasenplatten bei einer anfänglichen Zelldichte von 2*10⁵ Zellen/Locher gepflanzt und mit 25 µM Taurohyocholic Acid für 1 Stunde behandelt. Das Zellmedium wurde von den Zellen entfernt, bei 2000 g für 10 Minuten centrifugiert, um Zellrückstände zu entfernen, und das Überstandsmedium wurde gesammelt. Ein GLP-1-ELISA-Kit wurde verwendet, um GLP-1 zu bestimmen. |
Reaktionsbedingungen | 25µM, 1Stunde |
Anwendungen | Die Taurohyocholic Acid kann die Sekretion von GLP-1 in STC-1 Zellen. |
References: | |
| Cas No. | 32747-07-2 | SDF | |
| Überlieferungen | Tauro-γ-muricholic Acid | ||
| Chemical Name | 2-[[(3α,5β,6α,7α)-3,6,7-trihydroxy-24-oxocholan-24-yl]amino]-ethanesulfonic acid | ||
| Canonical SMILES | O[C@@H]1CC[C@@]2(C)[C@@]([C@@H](O)[C@@H](O)[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]4([H])[C@H](C)CCC(NCCS(O)(=O)=O)=O)([H])C1 | ||
| Formula | C26H45NO7S | M.Wt | 515.7 |
| Löslichkeit | 20mg/mL in ethanol, or DMSO, 30mg/mL in DMF | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9391 mL | 9.6956 mL | 19.3911 mL |
| 5 mM | 387.8 μL | 1.9391 mL | 3.8782 mL |
| 10 mM | 193.9 μL | 969.6 μL | 1.9391 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)















